Congestive Heart Failure: The Complication That Gets No Respect
|
|
- Vanessa Eaton
- 5 years ago
- Views:
Transcription
1 Number of Americans with HF (millions) Projected cost of HF (billions of dollars) Congestive Heart Failure: The Complication That Gets No Respect 65th Advanced Postgraduate Course February 9-11, 18, San Francisco, CA Sanjay Kaul, MD, FACC, FAHA Division of Cardiology Cedars-Sinai Medical Center Los Angeles, California Faculty/Presenter Disclosure Faculty Name: Sanjay Kaul, MD Advisor/Consultant - United States FDA Consultant - Boehringer Ingelheim - Sanofi - Novo Nordisk - Johnson & Johnson Stocks/Equity - Johnson & Johnson Congestive Heart Failure (in TDM): The Complication That Gets No Respect Congestive Heart Failure (in TDM): The Complication That Gets No Respect Outline Impact of heart failure Classification, prognosis, and medical management Epidemiology of TDM and heart failure Pathophysiology of TDM and heart failure Glucose-lowering medications and heart failure Heart failure outcomes in recent CVOTs in TDM Possible mechanisms for cardiovascular benefits Current trials with SGLT inhibitors in heart failure Take-home points HF is a Global Health Problem with a Prevalence of Approximately 6 million Worldwide Proportion of the population living with heart failure (HF) in individual countries across the world North America 1 Canada 1.5% USA 1.9% Europe 1 France.% UK 1.3% Latin America and Africa 1 No population-based estimates Middle East 1 Oman*.5% Australasia 1 Australia 1.3% Asia 1 China* 1.3% Japan 1.% Malaysia* 6.7% Singapore* 4.5% *Estimates based on a single centre or hospital Ponikowski P et al. Heart failure: Preventing disease and death worldwide. European Society of Cardiology, (accessed Nov 15) The Prevalence and Cost of HF is Projected to Increase Further Prevalence of HF (US) 5.8m 8.5m $31b Cost of HF* (US) $7b 1 3 * 8% of costs are related to Heidenreich et al., AHA Policy Statement: Forecasting the Impact of Heart Failure in the United States. Circ Heart Fail. 13;6:66 619
2 Deaths (% patients) Risk-adjusted 1-year mortality (%) There Scientific are Two Evidence Categories Underlying of Heart The Failure ACC/AHA HF preserved Clinical EF Practice Guidelines 1 HF reduced EF 3 LVEF 5% Caveat *, (4 5 borderline) LVEF 4% Emptor, Caveat Lector Attributed to pro-inflammatory CV and non-cv coexisting conditions 1 Occurs due to loss of systolic function 4 There Scientific are Two Evidence Categories Underlying of Heart The Failure ACC/AHA Clinical Practice Guidelines Caveat Emptor, Caveat Lector Associated with: hypertension, obesity, diabetes, metabolic syndrome, lung disease, smoking, and iron deficiency 1 HFpEF is less well understood than HFrEF 1, Accounts for >5% of all HF cases; 1% per year increase in prevalence 3 Leading cause: coronary artery disease 4 Associated with: coronary artery disease risk factors, e.g. hypertension, diabetes, advanced age, smoking, dyslipidemia 4 Accounts for 5% of all HF cases Important classification for clinical management,4 1. Redfield MM et al. N Engl J Med 16;375:1868;. Bugger H et al. Diabetologia 14;57:66; 3. Borlaug BA. Heart failure with preserved ejection fraction. In: Springer Verlag; 15; Mann DL et al. Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine, Single Volume, 1th Edition. Elsevier Saunders, Philadelphia 15 HFpEF Preserved systolic LV function No LV dilation Concentric LV remodeling Diastolic LV dysfunction HFrEF Systolic LV dysfunction LV dilation Eccentric LV remodeling Diastolic LV dysfunction Classification of HF: ACCF/AHA stage vs NYHA classification ACCF/AHA Stage NYHA Classification Heart Failure Risk Factors The Framingham Heart Study Age and Risk-factor Adjusted HR A At high risk for HF but without structural heart disease or symptoms of HF None B Structural heart disease but without signs or symptoms of HF I I No limitation of physical activity. Ordinary physical activity does not cause symptoms of HF. Same as above 6% (PAR) 1% (PAR) C Structural heart disease with prior or current symptoms of HF II III Slight limitation of physical activity. Comfortable at rest, but ordinary physical activity results in symptoms of HF. Marked limitation of physical activity. Comfortable at rest but less than ordinary activity causes symptoms of HF. 39% (PAR) 59% (PAR) 34% (PAR) 13% (PAR) IV Unable to carry on any physical activity without symptoms of HF or symptoms of HF at rest. D Refractory HF requiring specialized interventions IV Unable to carry on any physical activity without symptoms of HF or symptoms of HF at rest. NYHA: New York Heart Association, HF: heart failure Yancy CW, et al. Circulation. 13 ;18(16):e4 37. Hypertension and CAD are the most common risk factors for HF Levy D, et al. JAMA 1996;75: Not all Heart Failure Patients have a History of CAD HFpEF Study CAD HFrEF Study CAD TOPCAT 1 (n=3445) 59% PARADIGM-HF 7 (n=844) 6% I-Preserve (n=4133) 48% RALES 8 (n=1663) 55% CHARM-Preserved 3 (n=33) 6% COPERNICUS 9 (n=89) 67% Mortality Rates after HHF Results from Two Population-Based Cohort Studies 6 4 Mortality rates after HHF (ARIC study) Mortality rates after HHF (US Acute Care) * DIG-PEF 4 (n=988) 56% MERIT-HF 1 (n=3991) 65% PEP-CHF 5 (n=85) 7% CHARM-ALT 11 (n=8) 68% 1 1 SENIORS 6 (n=75) 77% SOLVD 1 (n=569) 71% 1 Pitt, B. et al. N Engl J Med. 14;37: ; Massie, B. et al. N Engl J Med 8;359: ; 3 Yusuf, S. et al. Lancet. 3 Sep 6; 36(9386): ; 4 Ahmed A, et al. Circulation 6;114:397 43; 5 Cleland, J, et al. Eur Heart J. 6 Oct;7(19): ; 6 Flather, M et al. Eur Heart J. 5 Feb;6(3):15 5; 7 McMurray, J. et al. N Engl J Med 14; 371:993 14; 8 Pitt, B. et al. N Engl J Med 1999:341:79 717; 9 Packer et al. N Engl J Med. 1; 344: ; 1 Merit HF Study Group. The Lancet. 1999;353:1-1; 11 Granger, C et al. Lancet 3; 36:77 776; 1 SOLVD Study Investigators N Engl J Med 1991;35:93 3. Day 3 Year 1 Year Time after *Risk-adjusted rates relative to year mortality of 31.7% Prognosis after for HF (HHF) is poor 1. Loehr LR et al. Am J Cardiol 8;11:116;. Chen J et al. JAMA 11;36:1669
3 Prevalence of diabetes (%) Hazard ratio (mortality) Repeat Hospitalization Leads to Worse Patient Outcomes 4% of patients died after discharge from HF Guidelines for Management of HFrEF (Stage C/D) 17 ACC/AHA/HFSA Focused Update Class I Benefit>>>Risk Class IIa Benefit >>Risk Time since discharge (months) 3 rd HF Hospitalization 1 st HF Hospitalization nd HF Hospitalization Adapted from Solomon SD et al. Circulation. 7;116: Yancy CW et al, Circulation. 17 ACC/AHA/HFSA HF Focused Update of the 1 ACCF/AHA Guidelines for the Management of Heart Failure. DOI: /CIR.59. Magnitude of Benefit Demonstrated in RCTs Class I LOE A Recommended Therapy Guideline-directed therapy RR reduction in mortality 1, NNT for mortality reduction (over 1 year) 1 RR reduction in HHF ACE inhibitor or ARB 17% 77 31% Beta blocker 34% 8 41% Aldosterone antagonist 3% 18 35% Hydralazine/nitrate 43% 1 33% ARNI 16% 8 1% 3 Benefit of therapy evident on the background of standard of care (incremental treatment effects) 1 Fonarow,G. et al. JAMA Cardiol. 16;1(6): ; Yancy CW et al. Circulation. 13;18:e4 e37; 3 McMurray, J. et al. N Engl J Med 14; 371: Guidelines for Management of HFpEF 17 ACC/AHA/HFSA Focused Update Recommendations 3 COR LOE Systolic and diastolic blood pressure should be controlled according to published clinical practice guidelines Diuretics should be used for relief of symptoms due to volume overload I C Coronary revascularization for patients with CAD in whom angina or demonstrable myocardial ischemia is present despite GDMT Management of AF according to published clinical practice guidelines for HFpEF to improve symptomatic HF Use of beta-blocking agents, ACE inhibitors, and ARBs for hypertension in HFpEF IIa C ARBs might be considered to decrease s in HFpEF IIb B In appropriately selected patients* with HFpEF aldosterone receptor antagonists might be considered to decrease s4 IIb B-R *Appropriately selected patients: with EF 45%, elevated BNP levels or HF admission within 1 year, estimated glomerular filtration rate >3 ml/min, creatinine <.5 mg/dl, potassium <5. meq/l No treatment has yet been shown, convincingly, to reduce morbidity and mortality in patients with HFpEF Yancy CW et al, Circulation. 17 ACC/AHA/HFSA HF Focused Update of the 1 ACCF/AHA Guidelines for the Management of Heart Failure. DOI: /CIR.59. I IIa IIa B C C Therapies Successful in HFrEF Have Not Demonstrated Success in HFpEF Diabetes is Common Among Patients with HF 6 Intervention HFrEF HFpEF Beta blocker SENIORS 1 OPTIMIZE-HF14 ACEi/ARB CHARM I-PRESERVE15 PEP-CHF 16 Digoxin DIG 3 Dig-PEF17 PDE5 inhibitor RELAX-HF 4 RELAX-HF4 MRA Hydralazine/Ni CRT ICD Exercise RALES 5 TOPCAT 18 EMPHASIS 6 ALDO-HF 19 A-HeFT 7 Cohn 8 MADIT-CRT 9 COMPANION 1 IMPROVE-HF 9 MADIT-I 11 HF-ACTION 1 Thompson et al. 13 NEAT-HFpEF PROSPECT1 No studies available Pandey* Evidence of clinical efficacy No evidence of clinical efficacy Clinical efficacy uncertain TOPCAT 1 RELAX SOCRATES -P 3 EPHESUS 4 PARADIGM 5 SOCRATES-R 6 GWTG HF 7 OPTIMIZE 8 ADHERE 9 (n=3345) (n=16) (n=477) (n=664) (n=8399) (n=456) (n=1,78) (n=46,61) (n=46,61) HFpEF RCTs HFrEF RCTs Registries Prevalence of DM in HF is 5-3% overall, 4-45% in those hospitalized for HF 1 Pitt B et al. N Engl J Med 14;39:1383; Redfield MM et al. JAMA 13;39:168; B et al. Eur Heart J 16;38:1119; 4 Pitt B et al. N Engl J Med 3;348:139; 5 McMurray JJV et al. N Engl J Med 14;371:993; 6 Gheorghiade M et al. JAMA 15;314:51; 7 Luo N et al. JACC Heart Fail 17;5:35; 8 Greenberg BH et al. Heart J 7;154:77.e177.e8; 9 Peacock F, et al. N Engl J Med 8; 358:
4 Cumulative incidence of CV death or HHF (%) Chest wall restriction, reduced vital capacity, impaired ventilation and diffusion Obstructive sleep apnea Pulmonary hypertension Direct and indirect myocardial lipotoxicity Worsened cardiac mechanics Diastolic dysfunction; increased filling pressures/ volume overload, increased afterload Non-alcoholic fatty liver disease Promotes generalized inflammatory state Inflammatory cytokines Adverse neurohormones Increased BNP clearance Direct toxic effects of perinephric fat Glomerulomegaly with glomerular dysfunction Increased adipose infiltration Impaired perfusion Decreased diffusive O transport Mitochondrial dysfunction Cumulative incidence (%) Cumulative incidence (%) There is a Strong Relationship Between Heart Failure and Diabetes 5 5 TDM Confers Higher Risk of CV death, Hospitalization for Heart Failure and All-cause Mortality CV death or due to heart failure CV death Low EF Low EF Diabetes 657/136 (5.3%) 413/136 (31.6%) No diabetes 114/37 (33.8%) 77/37 (1.6%) 6 4 CV death or due to heart failure a Follow-up (years) Diabetes (Low EF) No Diabetes (Low EF) People with diabetes have a - to 5-fold higher risk of developing HF (independent of IHD or HTN) 1 Diabetes confers 6 8% greater probability of CV death and all-cause mortality in those with established HF,3 * Hospitalization due to heart failure All-cause mortality Low EF Low EF 449/136 (34.4%) 496/136 (38.%) 79/37 (1.7%) 854/37 (6.1%) 6 4 All-cause mortality Diabetes (Low EF) No Diabetes (Low EF) 1. Kannel WB et al. Am J Cardiol 1974;34:9. Cubbon RM et al. Diab Vasc Dis Res 13;1:33 3. MacDonald MR et al. Eur Heart J 8;9:1377 MacDonald MR, et al. Eur Heart J 8;9: Follow-up (years) Diabetes Increases Risk in HFpEF to Approximate Risk in HFrEF in Non-DM Patients with Heart Failure have Similar Pathophysiological Features as Patients with Diabetes Increased risk of or death due to HF with HFrEF vs HFpEF 6 1 HFrEF: adjusted HR 1.6 Non-Diabetes Diabetes 95% CI 1.4, 1.77; p<.1 HFrEF HFpEF: adjusted HR. 4 95% CI 1.7,.36; p<.1 HFpEF HFrEF 1 HFpEF Heart failure Impaired contractility Cardiomyocyte apoptosis/fibrosis Neurohormonal activation LV remodelling Shared pathological features Endothelial dysfunction Insulin resistance Mitochondrial dysfunction RAAS activation Inflammation Diabetes Hyperglycaemia Pancreatic beta-cell function Advanced glycated end-product toxicity Neuronal degeneration/ demyelination Follow-up (years) MacDonald MR et al. Eur Heart J 8;9:1377 LV, left ventricular; RAAS, renin-angiotensin-aldosterone system Adapted from: Sena CM et al. BBA Mol Basis Dis 13;183:16; Aroor AR et al. Heart Fail Clin 1;8:69; Anker SD et al. Heart 4;9:464; Sivitz WI et al. Antioxid Redox Signal 1;1:557; Bauters C et al. Cardiovasc Diabetol 3;:1 Diabetes Contributes to the Progression of Heart Failure HFpEF in 18: Phenotypic Diversity Lung Heart Liver Visceral adiposity Kidney Skeletal muscle Obesity-related HFpEF is the most common phenotype of heart failure in TDM Perrone-Filardi P et al. Eur Heart J. 15;36(39): Kitzman D, Shah SJ. JACC 16 Borlaug B. Nat Rev Cardiol 14
5 TZDs* GLP-1 R DDP-4 inhibitors* Intensive Glycaemic Control* Has Not Been Shown to Significantly Impact the Risk of HF Previous CV Outcomes s with Glucose-Lowering Agents Have Not Shown a Benefit for HF Outcomes Number of events (yearly rate, %) DHbA1c HR (95% CI) (%) More intensive Less intensive Admission to hospital/fatal HF ACCORD 15 (.9) 14 (.75) (.93, 1.49) ADVANCE (.83) 31 (.88).7.95 (.79, 1.14) UKPDS 8 (.6) 6 (.11) (.19, 1.6) VADT 79 (1.8) 85 (1.94) (.68, 1.5) Overall (.86, 1.16) agonists* Insulin* Study drug Comparator n (%) n (%) HR (95% CI) ORIGIN (HHF) 31 (4.9) 343 (5.5).9 (.77, 1.5) SAVOR-TIMI 53 (HHF) 89 (3.5) 8 (.8) 1.7 (1.7, 1.51) EXAMINE (HHF) 16 (3.9) 89 (3.3) 1.19 (.9, 1.58) TECOS (HHF) 8 (3.1) 9 (3.1) 1. (.83, 1.) TECOS (HHF or CV death) 538 (7.3) 55 (7.) 1. (.9, 1.15) ELIXA (HHF) 1 (4.) 17 (4.).96 (.75, 1.3) ELIXA (HHF or 4P-MACE) 456 (15.) 469 (15.5).97 (.85, 1.1) *Versus less-intensive glycaemic control; p=.31 for heterogeneity from Q test with significance cut off of p=.1 Favours more intensive control Favours less intensive control PROactive (HHF or HF death) 149 (5.7) 18 (4.1) 1.41(1.1, 1.8) RECORD (HHF or CHF death) 61 (.7) 9 (1.3).1 (1.35, 3.7) Vildagliptin increased ventricular end-diastolic volume in pts with reduced LV fx (VIVIDD) Liraglutide increased (ns) the rate of death or hhf in pts recently hospitalized for HF (FIGHT) Favours study drug Favours comparator Excess adverse cardiac events with Liraglutide in chronic HF with or without DM (LIVE) Turnbull FM et al. Diabetologia 9;5:88 Metformin in Heart Failure Compared With Other Treatments For All-cause Mortality Congestive Heart Failure (in TDM): The Complication That Gets No Respect Risk ratio Study or IV, random, 95% CI subgroup log[risk ratio] SE Weight Year Evans %.6 (.37,.98) 5 Eurich %.66 (.45,.98) 5 Masoudi %.87 (.77,.98) 5 Inzucchi %.9 (.71, 1.19) 5 Shah %.79 (.36, 1.73) 1 MacDonald %.65 (.48,.87) 1 Roussel %.69 (.53,.89) 1 Andersson %.85 (.74,.97) 1 Aguilar %.76 (.6,.9) 11 Total (95% CI) 1.%.8 (.74,.87) Heterogeneity: Tau =.; Chi =9.45, df=8 (P=.31); I =15% Test for overall effect: Z=5.35 (P<.1) Eurich DT, et al. Circ Heart Fail 13;6:395 4 Favors Metformin Control Impact of heart failure Classification, prognosis, and medical management Epidemiology of TDM and heart failure Pathophysiology of TDM and heart failure Glucose-lowering medications and heart failure Heart failure outcomes in recent CVOTs in TDM Possible mechanisms for cardiovascular benefits Current trials with SGLT inhibitors in heart failure Take-home points 8 FDA Diabetes Guidance Recommendations Primary evidence for regulatory approval: glycemic control Demonstrate that therapy will not result in an unacceptable increase in CV risk (noninferiority, rule out HR 1.3) Phase /3 design should permit a pre-specified meta-analysis of major cardiovascular events (3p-MACE: CV death, non-fatal MI, or non-fatal stroke; 4-p MACE = 3-p MACE + hosp. for UA or CR) (4p-MACE to r/o 1.8, 3p-MACE to r/o 1.3) Independent committee should prospectively and blindly adjudicate MACE s should include patients at increased risk for cardiovascular disease (advanced CVD, CKD, elderly) duration(s) should be longer than 3-6 months to obtain enough events and provide long-term data (~yrs) No mention of heart failure outcome assessment in Diabetes Guidance! CVOTs in TDM: Evidentiary Landscape 5 s (9 Completed), N=, since 13 SAVOR-TIMI 53 n = 16,49 EXAMINE n = 5,38 13 DPP-4 inhibitors SGLT inhibitors GLP-1 receptor agonists Insulin TZD α-glucosidase inhibitor EMPA-REG OUTCOME n = 7, * ELIXA n = 6,68 TECOS n = 14,671 CARMELINA n = 8,3, renal composite REWIND n = 9,91 CAROLINA n = 6, * LEADER n = 9,34 SUSTAIN-6 n = 3,97 * CANVAS Program n = 1,14 * DEVOTE n = 7,637 IRIS n = 3,876 Fatal or nonfatal stroke or MI FREEDOM-CVO n = 4, EXSCEL n = 14,75 ACE n = 6,56 5-P MACE ( + for HF or unstable angina) VERTIS CV n = 8, Dapa-HF n = 4,5 CV death, HF, HF urgent visit PIONEER 6 n = 3,176 HARMONY Outcomes n = 9,4 CREDENCE n = 4, ESRD, doubling of creatinine, renal/cv death DECLARE-TIMI 58 n = 17,15, CVD EMPEROR- Preserved n = 4,16 CV death or HF EMPEROR- Reduced n =,85 CV death or HF Dapa-CKD n = 4, 5% sustained decline in egfr or reaching ESRD or CV death or renal death
6 Spectrum of CV Risk of Target Patient Population of Key CVOTs of Glucose-Lowering Therapies Select Therapeutic Effects of Glucose-Lowering Therapies on HF and CV Outcomes DECLARE-TIMI 58 EMPEROR-Reduced EMPEROR-Preserved HF Outcomes + (Benefit) CV Outcomes +/- (Null) - (Harm) Dapa-HF + (Benefit) Empaglifozin (EMPA-REG OUTCOME) Canagliflozin (CANVAS) +/- (Null) Liraglutide (LEADER) Semaglutide (SUSTAIN-6) Insulin Glargine (ORIGIN) Acarbose (ACE) Lixisenatide (ELIXA) Exanetide (EXSCEL) Alogliptin (EXAMINE) Sitagliptin (TECOS) - (Harm) Pioglitazone (PROactive) Rosiglitazone (RECORD) Saxagliptin (SAVOR-TIMI 53) Borrowed from Javed Butler, MD (Circulation 18, In Press) Prevalence of Heart Failure in Recent Diabetes CVOTs F/U, y (median) Age, y BMI Male (%) Duration of DM, y H/O of CVD Baseline H/O HF HbA1c, baseline (D) SAVOR % 13% 8. (-.3) EXAMINE % 8% 8. (-.3) TECOS % 18% 7. (-.3) ELIXA % % 7.7 (-.3) LEADER % 18% 8.7 (-.4) SUSTAIN % 4% 8.7 (-.7, -1.) EXCSEL % 16% 8. (-.5) EMPA-REG >1y (57%) 99% 1% 8.1 (-.3) CANVAS % 14% 8. (-.6) Heart failure not specified as an inclusion criterion in any trial! Heart Failure Outcomes in Recent Diabetes CVOTs PEP SEP (prespecified) Yes Powered SAVOR No Yes No EXAMINE* No No No TECOS No Yes No ELIXA No Yes No LEADER No Yes No SUSTAIN-6 No Yes No EXCSEL No Yes No EMPA-REG No Yes No CANVAS Program No Yes No *post hoc Hospitalization for heart failure (HHF) not prespecified as a primary endpoint or as a powered secondary endpoint in any trial! Heart Failure Outcomes in Recent IGT/TDM CVOTs NAVIGATOR (NEJM 1) (Valsartan/nateglinide vs placebo in pts with impaired glucose tolerance and established CV disease or risk factors) ORIGIN (NEJM 1) (Insulin glargine vs standard of care in pts with CV risk factors plus impaired fasting glucose, impaired glucose tolerance TDM) ACE (Lancet 17) (Acarbose vs placebo in Chinese pts with coronary heart disease and impaired glucose tolerance) Primary endpoint Development of diabetes CV death, nonfatal MI, nonfatal stroke, arterial revascularization, for heart failure, or for unstable angina CV death, nonfatal MI, nonfatal stroke, for heart failure CV death, nonfatal MI, nonfatal stroke CV death, nonfatal MI, nonfatal stroke, revascularization, for heart failure CV death, nonfatal MI, nonfatal stroke, for heart failure, or for unstable angina Hospitalization for heart failure (HHF) prespecified as a component of primary composite endpoint in trials of IGT and 1 trial of IGT/TDM! CVOTs in TDM: HF Outcome as Primary Endpoint 5 s (9 Completed), N=, since 13 SAVOR-TIMI 53 n = 16,49 EXAMINE n = 5,38 13 DPP-4 inhibitors SGLT inhibitors GLP-1 receptor agonists Insulin TZD α-glucosidase inhibitor EMPA-REG OUTCOME n = 7, ELIXA n = 6,68 TECOS n = 14,671 CARMELINA n = 8,3, renal composite REWIND n = 9,91 CAROLINA n = 6, LEADER n = 9,34 SUSTAIN-6 n = 3,97 CANVAS Program n = 1,14 DEVOTE n = 7,637 IRIS n = 3,876 Fatal or nonfatal stroke or MI FREEDOM-CVO n = 4, EXSCEL n = 14,75 ACE n = 6,56 5-P MACE ( + for HF or unstable angina) VERTIS CV n = 8, Dapa-HF n = 4,5 CV death, HF, HF urgent visit PIONEER 6 n = 3,176 HARMONY Outcomes n = 9,4 CREDENCE n = 4, ESRD, doubling of creatinine, renal/cv death DECLARE-TIMI 58 n = 17,15, CVD EMPEROR- Preserved n = 4,16 CV death or HF EMPEROR- Reduced n =,85 CV death or HF Dapa-CKD n = 4, 5% sustained decline in egfr or reaching ESRD or CV death or renal death Co-primary endpoint in DECLARE-TIMI 58: CV death or HHF
7 Patients with event (%) Patients with event (%) Death or heart failure re - rate Heart Failure Outcomes in Recent Diabetes CVOTs PEP Hosp. CV death MI Stroke (MACE) for HF (HHF) SAVOR EXAMINE* TECOS ELIXA LEADER SUSTAIN EXCSEL EMPA-REG CANVAS Program *post hoc HHF as common as other nonfatal MACE endpoints Heart Failure Outcomes in Recent Diabetes CVOTs Drug %, IR/1PY Hospitalization for Heart Failure (HHF) Control %, IR/1PY HR (95%CI) SAVOR 89 (3.5%) 8 (.8%) 1.7 ( ) EXAMINE 16 (3.9%) 89 (3.3%) 1.19 ( ) TECOS 8 (1.7) 9 (1.9) 1. (.83-1.) ELIXA 17 (4.) 1 (4.).96 ( ) LEADER 18 (1.) 48 (1.4).87 ( ) SUSTAIN-6 59 (3.6) 54 (3.3) 1.11 ( ) EXCSEL 19 (3.%) 31 (3.1%).94 ( ) EMPA-REG 95 (.94) 1 (1.45).65 (.5.85) CANVAS Program 13 (.55) 1 (.87).67 (.5.87) risk of HHF with DPP4i, null outcomes with GLP-1 RA, risk with SGLT inhibitors Hospitalisation for Heart Failure in DPP4i CVOTs Updated FDA Label DPP4i (saxagliptin) DPP4i (alogliptin) DPP4i (sitagliptin) DPP4i (linagliptin) SAVOR-TIMI EXAMINE TECOS CAROLINA CARMELINA Impact on HHF compared with placebo HR 1.7; (95%CI ) p=.7 HR 1.19; (95%CI ) 4 p=. HR 1.; (95%CI.83-1.) 5 p=.98 Not completed FDA Label FDA guidance: May increase the risk of heart failure, particularly in patients who already have heart or kidney disease (4/5/16). 3 FDA guidance: May increase the risk of heart failure, particularly in patients who already have heart or kidney disease (4/5/16). 3 Consider the risks and benefits prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and renal impairment (8/1/17) Consider the risks and benefits prior to initiating treatment in patients at risk for heart failure, such as those with a prior history of heart failure and renal impairment (8/1/17) 1. Pfeffer M A et al., N Engl J Med 15;373:47;. Scirica BM et al. N Engl J Med 13;369:1317; 3. FDA Drug Safety Communication, Available at: (accessed April 16). 4. Zannad F et al. Lancet 15;385:67; 5. Green JB et al. N Engl J Med 15;373:3; Incretins in Heart Failure: Phase s FIGHT (Phase, LV EF <4%, n=3) Liraglutide vs placebo HR=1.96 (95% CI:.9, 1.83; P=.14) Days post-randomization Margulies, KB et al, JAMA. 16;316:5-8. Liraglutide Placebo LIVE - Phase, chronic HF, EF <45% with or without DM, n= 41, 4 wks - Excess adverse cardiac events with Liraglutide (1 v 3) VIVIDD - Phase, Class I-III HF, EF <4% with DM, n= 54, 4 wks - No difference in HF events - increased ventricular end-diastolic volume with vildagliptin Eur J Heart Fail. 17;19:69-77 (LIVE) JACC Heart Fail. 17 (VIVIDD). EMPA-REG OUTCOME: Empagliflozin Improved CV Outcomes in TDM Outcome Patients with event / analyzed Hazard ratio Empagliflozin Placebo 95% CI P value 3-point MACE 49/4687 8/ ,.99*.38 CV death 17/ / ,.77 <.1 Nonfatal MI 13/ / , EMPA-REG OUTCOME: Empagliflozin Improved CV Outcomes in TDM Death from any cause HR=.68 (95% CI:.57,.8) P<.1 Placebo Empagliflozin Hospitalization for heart failure HR=.65 (95% CI:.5,.85) P=. Placebo Empagliflozin Nonfatal stroke 15/4687 6/ , Hospitalization for 16/ / , heart failure No. at risk Month Empagliflozin Placebo No. at risk Month Empagliflozin Placebo Zinman B, et al. N Engl J Med 15;373: Zinman B, et al. N Engl J Med 15;373:117 18
8 Patients with an event (%) Patients with event/analysed (%) EMPA-REG OUTCOME: Reductions in HHF, CV death and All-cause Mortality Were Consistent in Patients with and without HF at Baseline 16 ESC Guidelines Recognise Empagliflozin for the Prevention or Delay of Heart Failure in TD Empagliflozin Placebo HR (95% CI) HR (95% CI) HHF or CV death All treatment All patients 65/4687 (5.7) 198/333 (8.5).66 (.55,.79) by subgroup HF at baseline interaction p>.4 1 No 19/45 (4.5) 149/89 (7.1).63 (.51,.78) Yes 75/46 (16.) 49/44 (.1).7 (.5, 1.4) HHF All patients 16/4687 (.7) 95/333 (4.1).65 (.5,.85) HF at baseline No 78/45 (1.8) 65/89 (3.1).59 (.43,.8) Yes 48/46 (1.4) 3/44 (1.3).75 (.48, 1.19) CV death All patients 17/4687 (3.7) 137/333 (5.9).6 (.49,.77) HF at baseline No 134/45 (3.) 11/89 (5.3).6 (.47,.77) Yes 38/46 (8.) 7/44 (11.1).71 (.43, 1.16) All-cause mortality All patients 69/4687 (5.7) 194/333 (8.3).68 (.57,.8) HF at baseline No 13/45 (5.) 159/89 (7.6).66 (.51,.81) Yes 56/46 (1.1) 35/44 (14.3).79 (.5, 1.) Favours empagliflozin Favours placebo Fitchett D et al. Eur Heart J 16;37:156 Empagliflozin should be considered in patients with Class Level TD in order to delay the onset of heart failure and IIa B prolong life Empagliflozin is not indicated for the treatment of heart failure Ponikowski P et al. Eur Heart J 16;37:19 Heart Failure Outcome in EMPA-REG OUTCOME Issues for Discussion Exploratory endpoint with no control for Type 1 error Endpoints redefined during trial Intensification of oral diuretic regimen used as a qualifying criteria Study not designed to explore effect on heart failure - Baseline prevalence (1%) likely under-reported - Functional class, EF, biomarkers not assessed - Concomitant medications and doses not well captured Heart failure outcome data not pivotal for label change or claim Hypothesis-generating that requires validation in future studies CANVAS Program Canagliflozin Improved CV Outcomes in TDM Patients with event/analysed Canagliflozin Placebo HR (95% CI) p-value 3P-MACE 585/ /4347 CV death 68/ /4347 Non-fatal MI 15/ /4347 Non-fatal stroke 158/ /4347 *P values not reported because all-cause mortality endpoint not met in the hierarchical test strategy.86 (.75,.97).87 (.7, 1.6).85 (.69, 1.5).9 (.71, 1.15) Favours canagliflozin Neal B et al. N Engl J Med 17; doi:1.156/nejmoa <.1 (non-inferiority). (superiority) Favours placebo NR* NR* NR* Superiority for 3P-MACE not prespecified in the testing hierarchy CANVAS Program Hospitalization for Heart Failure 8 Heart Failure Outcome in CANVAS Issues for Discussion HR.67 (95% CI.5,.87) Placebo Canagliflozin Exploratory endpoint with no control for Type 1 error Study not designed to explore effect on heart failure - Baseline prevalence (14%) likely under-reported - Functional class, EF, biomarkers not assessed 1 - Concomitant medications and doses not well captured Weeks since randomisation No. at risk Canagliflozin Placebo Intention-to-treat analysis. Exploratory outcome, no p-value is reported, only nominal effect estimate is given Neal B et al. N Engl J Med 17; doi:1.156/nejmoa Heart failure outcome data not pivotal for label change or claim Hypothesis-generating that requires validation in future studies
9 Kosiborod M et al. Circulation. 17;doi.org/1.1161/CIRCULATIONAHA SGLTi in Real World Practice: CVD-Real Registry Primary Outcomes Potential Mechanistic Links Between Glucose- Lowering Therapies and Heart Failure Risk Hospitalization for Heart Failure (HR.61) (Cana 53%, Dapa 4%, Empa 5%) All-cause Death (HR.49) (Cana 4%, Dapa 51%, Empa 7%) P hetero.169 P hetero.89 P<.1 P<.1 Inconsistent results for all-cause mortality, but not for heart failure between CANVAS and CVD-Real! Borrowed from Javed Butler, MD (Circulation 18, In Press) Potential CV & Renal Function Preservation Mechanisms of SGLTi that May Benefit Heart Failure Randomised Controlled s of SGLT Inhibitors in HF SGLT inhibition 1, Na+ removal Glucose removal Mechanism1 4 Possible cardio renal effects5,6 CV/renal outcomes observed in EMPA-REG OUTCOME 7,8 Osmotic diuresis Metabolism Sodium Cardiac function Arrhythmia Preload Afterload Cardiometabolic efficiency Arterial wall structure/function Renal function 1. Heise T et al. Diabetes Obes Metab 13;15:613;. Heise T et al. Clin Ther 16;38:65; 3. Ferrannini G et al. Diabetes Care 15;38:173; 4. Briand F et al. Diabetes 16;65:3; 5. Heerspink HJ et al. Circulation 16;134:75; 6. Inzucchi S et al. Diab Vasc Dis Res 15;1:9; 7. Zinman B et al. N Engl J Med 15;373:117; 8. Wanner C et al. N Engl J Med 16;375:33 CV death Hospitalisation for heart failure Renal events 1 EMPEROR-Preserved1 EMPEROR-Reduced Dapa-HF3 Sample size * 45 Key inclusion Patients with chronic HF Elevated NT-proBNP Symptomatic HFrEF Elevated NT-proBNP criteria egfr ml/min/1.73 m egfr 3 ml/min/1.73 m Primary endpoint Key secondary endpoints Start date: Expected completion date: HFpEF (LVEF >4%) HFrEF (LVEF 4%) HFrEF (LVEF 4%) Time to first occurrence of CV Time to first event of adjudicated CV death or adjudicated HHF death, HHF or urgent HF visit Individual components of primary endpoint All-cause mortality All-cause hospitalisation Time to first occurrence of sustained reduction of egfr Change from baseline in KCCQ March 17 June March 17 June Total number of HHF or CV death All-cause mortality Composite of 5% sustained egfr decline ESRD or renal death Change from baseline in KCCQ February 17 December Clinicals.gov NCT357951;. Clinicals.gov NCT357977; 3. Clinicals.gov NCT33614 Diabetes and Heart Failure Take Home Points Heart failure is a complex disease, with various etiologies and poor prognosis many treatments are available for HFrEF, but few are available for HFpEF TDM is a major risk factor for heart failure, and the prevalence of both is increasing Outcomes of patients with heart failure are poor, and worse with TDM, so there is a critical need for novel management strategies to improve outcomes in this high-risk group SGLT inhibitors have been shown to improve cardiovascular outcomes in patients with TDM, regardless of glycemic response Mechanisms of cardiovascular protection with SGLT inhibitors are likely to include increased natriuresis, increased hematopoiesis, and a possible shift in heart fuel metabolism Large trials of cardiovascular outcomes with SGLT inhibitors, as well as dedicated trials in patients with heart failure and a number of mechanistic studies, are ongoing. These trials will provide further insight into the cardiovascular and renal protective signals seen with this class of drugs
Update on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationCardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes
Biomarkers 2018 Cardiologists and HbA1c: Novel Diabetes Drugs and Cardiovascular Disease Outcomes Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationHeart Failure Management in T2 DM A Practical Approach. David Fitchett MD St Michael s Hospital Toronto
Heart Failure Management in T2 DM A Practical Approach David Fitchett MD St Michael s Hospital Toronto Faculty: Faculty Disclosure David Fitchett MD,, FRCP(C) Associate Professor of Medicine, University
More informationHFpEF, Mito or Realidad?
HFpEF, Mito or Realidad? Ileana L. Piña, MD, MPH Professor of Medicine and Epidemiology/Population Health Associate Chief for Academic Affairs -- Cardiology Montefiore-Einstein Medical Center Bronx, NY
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationCANVAS Program Independent commentary
CANVAS Program Independent commentary Cliff Bailey Aston University, Birmingham, UK 2017 Disclosures and disclaimers Clifford J Bailey CJB has attended advisory boards, undertaken ad hoc consultancy, received
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationNew Strategies for Cardiovascular Risk reduction in Diabetes
New Strategies for Cardiovascular Risk reduction in Diabetes Dr. Godwin LEUNG Tat Chi MB ChB(HK), MRCP (UK), FHKCP, FHKAM (Medicine) FRCP (Glasg), FACC Specialist in Cardiology % event as first CV event
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More informationTop HF Trials to Impact Your Practice
Top HF Trials to Impact Your Practice Biykem Bozkurt, MD, FACC The Mary and Gordon Cain Chair & Professor of Medicine Medical Care Line Executive, DeBakey VA Medical Center, Director, Winters Center for
More informationCongestive Heart Failure: Outpatient Management
The Chattanooga Heart Institute Cardiovascular Symposium Congestive Heart Failure: Outpatient Management E. Philip Lehman MD, MPP Disclosure No financial disclosures. Objectives Evidence-based therapy
More informationUpdates in Diabetes and Cardiovascular Disease Management: Are You Making the Link?
Updates in Diabetes and Cardiovascular Disease Management: Are You Making the Link? Denise Kolanczyk, PharmD, BCPS AQ Cardiology 1 Erika Hellenbart, PharmD, BCPS 2 Jennifer D Souza, PharmD, CDE, BC ADM
More informationDisclosures. Overview. Goal statement. Advances in Chronic Heart Failure Management 5/22/17
Disclosures Advances in Chronic Heart Failure Management I have nothing to disclose Van N Selby, MD UCSF Advanced Heart Failure Program May 22, 2017 Goal statement To review recently-approved therapies
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More information01/09/2017. Outline. SGLT 2 inhibitor? Diabetes Patients: Complex and Heterogeneous. Association between diabetes and cardiovascular events
MICROVASCULAR COMPLICATIONS Incidence of outcome g 1 Cardioprotective Effects of SGLT2s Relevant for Which T2 Diabetes Patient? SGLT 2 inhibitor? 58 year old, waist circumference 5 cm, PMH: IHD On statin,
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationDiabetes and Heart Failure: Challenges and Opportunities
AHA Get With The Guidelines-Heart Failure Webinar Diabetes and Heart Failure: Challenges and Opportunities Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA
More informationThe ACC Heart Failure Guidelines
The ACC Heart Failure Guidelines Fakhr Alayoubi, Msc,R Ph President of SCCP Cardiology Clinical Pharmacist Assistant Professor At King Saud University King Khalid University Hospital Riyadh-KSA 2017 ACC/AHA/HFSA
More informationThe EMPA-REG OUTCOME trial: Design and results. David Fitchett, MD University of Toronto, Canada
The EMPA-REG OUTCOME trial: Design and results David Fitchett, MD University of Toronto, Canada Asian Cardio Diabetes Forum April 23 24, 2016 Kuala Lumpur, Malaysia Life Expectancy Is Reduced by ~12 Years
More informationTreating HF Patients with ARNI s Why, When and How?
Treating HF Patients with ARNI s Why, When and How? 19 th Annual San Diego Heart Failure Symposium for Primary Care Physicians January 11-12, 2019 La Jolla, CA Barry Greenberg M.D. Distinguished Professor
More informationTherapeutic Targets and Interventions
Therapeutic Targets and Interventions Ali Valika, MD, FACC Advanced Heart Failure and Pulmonary Hypertension Advocate Medical Group Midwest Heart Foundation Disclosures: 1. Novartis: Speaker Honorarium
More informationESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES
ESC GUIDELINES ON DIABETES AND CARDIOVASCULAR DISEASES Pr. Michel KOMAJDA Institute of Cardiology - IHU ICAN Pitie Salpetriere Hospital - University Pierre and Marie Curie, Paris (France) DEFINITION A
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationDisclosures. Advances in Chronic Heart Failure Management 6/12/2017. Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017
Advances in Chronic Heart Failure Management Van N Selby, MD UCSF Advanced Heart Failure Program June 19, 2017 I have nothing to disclose Disclosures 1 Goal statement To review recently-approved therapies
More informationPreserved EF with heart failure (HF pef) 50% 5 year survival. Both have type 2 diabetes Both have hypertension Both have normal ejection fractions
Research companies Government / University research Preserved EF with heart failure (HF pef) 50% 5 year survival Both have type 2 diabetes Both have hypertension Both have normal ejection fractions Introduction
More informationHeart Failure Background, recognition, diagnosis and management
Heart Failure Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of heart failure
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationHeart Failure A Team Approach Background, recognition, diagnosis and management
Heart Failure A Team Approach Background, recognition, diagnosis and management Speaker bureau: Novartis At the conclusion of this activity, participants will be able to: Recognize signs and symptoms of
More informationOutline. Classification by LVEF Conventional Therapy New Therapies. Ivabradine Sacubitril/valsartan
New Pharmacological Therapies for Heart Failure Mark Drazner, MD, MSc Clinical Chief of Cardiology Medical Director, CHF/VAD/Transplant James M. Wooten Chair in Cardiology UT Southwestern Medical Center
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationUPDATES IN MANAGEMENT OF HF
UPDATES IN MANAGEMENT OF HF Jennifer R Brown MD, MS Heart Failure Specialist Medstar Cardiology Associates DC ACP Meeting Fall 2017 Disclosures: speaker bureau for novartis speaker bureau for actelion
More informationHeart Failure Guidelines For your Daily Practice
Heart Failure Guidelines For your Daily Practice Juan M. Aranda, Jr., MD, FACC, FHFSA Professor of Medicine Director of Heart Failure and Cardiac Transplantation University of Florida College of Medicine
More informationDrugs acting on the reninangiotensin-aldosterone
Drugs acting on the reninangiotensin-aldosterone system John McMurray Eugene Braunwald Scholar in Cardiovascular Diseases, Brigham and Women s Hospital, Boston & Visiting Professor, Harvard Medical School
More informationThe Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF)
The Approach to Patients with Heart Failure and Mid-Range (40-50%) Ejection Fraction (HFmrEF) 22 nd Annual Heart Failure 2018 an Update on Therapy April 21, 2018 Los Angeles, CA Barry Greenberg, M.D. Distinguished
More informationDapagliflozin and cardiovascular outcomes in type 2
EARN 3 FREE CPD POINTS diabetes Leader in digital CPD for Southern African healthcare professionals Dapagliflozin and cardiovascular outcomes in type 2 diabetes Introduction People with type 2 diabetes
More informationHEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD
HEART FAILURE AND DIABETES MELLITUS: DANGEROUS LIASONS MICHEL KOMAJDA, MD Author affiliations: Department of Cardiology, Hôpital Saint Joseph, Paris, France Address for correspondence: Michel Komajda,
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More information2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure
2017 ACC/AHA/HFSA Focused Update of the 2013 ACCF/AHA Guideline for the Management of Heart Failure Developed in Collaboration With the American Academy of Family Physicians, American College of Chest
More informationESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure
ESC Guidelines for the Diagnosis and Treatment of Chronic Heart Failure - 2005 Karl Swedberg Professor of Medicine Department of Medicine Sahlgrenska University Hospital/Östra Göteborg University Göteborg
More informationHFpEF. April 26, 2018
HFpEF April 26, 2018 (J Am Coll Cardiol 2017;70:2476 86) HFpEF 50% or more (40-71%) of patients with CHF have preserved LV systolic function. HFpEF is an increasingly frequent hospital discharge. Outcomes
More informationSoo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital
Soo LIM, MD, PHD Internal Medicine Seoul National University Bundang Hospital Agenda Association between Cardiovascular Disease and Type 2 Diabetes Importance of HbA1c Management esp. High risk patients
More informationSGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection
SGLT2 inhibition in diabetes: extending from glycaemic control to renal and cardiovascular protection Hiddo Lambers Heerspink Department of Clinical Pharmacy and Pharmacology University Medical Center
More informationUpdates in Congestive Heart Failure
Updates in Congestive Heart Failure GREGORY YOST, DO JOHNSTOWN CARDIOVASCULAR ASSOCIATES 1/28/2018 Disclosures Edwards speaker on Sapien3 valves (TAVR) Stages A-D and NYHA Classes I-IV Stage A: High risk
More informationThe Clinical Unmet need in the patient with Diabetes and ACS
The Clinical Unmet need in the patient with Diabetes and ACS Professor Kausik Ray (UK) BSc(hons), MBChB, MD, MPhil, FRCP (lon), FRCP (ed), FACC, FESC, FAHA Diabetes is a global public health challenge
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationHeart Failure with Preserved EF (HFPEF) Epidemiology and management
Heart Failure with Preserved EF (HFPEF) Epidemiology and management Karl Swedberg Senior Professor of Medicine Sahlgrenska Academy University of Gothenburg Gothenburg, Sweden e-mail: karl.swedberg@gu.se
More informationACE inhibitors: still the gold standard?
ACE inhibitors: still the gold standard? Session: Twenty-five years after CONSENSUS What have we learnt about the RAAS in heart failure? Lars Køber, MD, D.Sci Department of Cardiology Rigshospitalet University
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationDiabetes new challenges, new agents, new order
Diabetes new challenges, new agents, new order Ken Earle St Georges University Hospitals NHS Foundation Trust Overview Cardiovascular disease unmet needs Treating evident and residual risk Integrating
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationObjectives. Systolic Heart Failure: Definitions. Heart Failure: Historical Perspective 2/7/2009
Objectives Diastolic Heart Failure and Indications for Echocardiography in the Asian Population Damon M. Kwan, MD UCSF Asian Heart & Vascular Symposium 02.07.09 Define diastolic heart failure and differentiate
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationCurrent Updates & Challenges In Managing Diabetes in CVD
Current Updates & Challenges In Managing Diabetes in CVD Preventive Cardiovascular Conference 2016 Instituit Jantung Negara 12 th November 2016 Nor Azmi Kamaruddin Diabetes Clinic Department of Medicine
More informationChecklist for Treating Heart Failure. Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute
Checklist for Treating Heart Failure Alan M. Kaneshige MD, FACC, FASE Oklahoma Heart Institute Novartis Disclosure Heart Failure (HF) a complex clinical syndrome that arises secondary to abnormalities
More informationThe Flozins Quest for Clarity?
The Flozins Quest for Clarity? Choosing Wisely with Academic Detailing 2018 ARE THEY THE REAL DEAL Disclosure statements The Academic Detailing Service is operated by Dalhousie Continuing Professional
More informationRikshospitalet, University of Oslo
Rikshospitalet, University of Oslo Preventing heart failure by preventing coronary artery disease progression European Society of Cardiology Dyslipidemia 29.08.2010 Objectives The trends in cardiovascular
More informationAldosterone Antagonism in Heart Failure: Now for all Patients?
Aldosterone Antagonism in Heart Failure: Now for all Patients? Inder Anand, MD, FRCP, D Phil (Oxon.) Professor of Medicine, University of Minnesota, Director Heart Failure Program, VA Medical Center 111C
More informationCardiovascular Impact of Medications for Treating Type 2 Diabetes
Friday CME Breakfast Lecture Cardiovascular Impact of Medications for Treating Type 2 Diabetes Thomas Blevins, MD Endocrinologist, Private Practice Texas Diabetes and Endocrinology Austin, Texas Educational
More informationFaiez Zannad. Institut Lorrain du Coeur et des Vaisseaux. CIC - Inserm
Faiez Zannad Institut Lorrain du Coeur et des Vaisseaux CIC - Inserm Disclosure Faiez Zannad Grants BG Medicine, Roche Diagnostics. Consultant/Steering committees/event committees/ Data safety Monitoring
More informationEmergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus
Emergence of the New Classes of Compounds for Managing Heart Disease in Diabetes Mellitus Mikhail Kosiborod, MD Professor of Medicine (Cardiology) Saint Luke s Mid America Heart Institute University of
More informationHEART FAILURE IN WOMEN. Marian Limacher, MD Division of Cardiovascular Medicine University of Florida
HEART FAILURE IN WOMEN Marian Limacher, MD Division of Cardiovascular Medicine University of Florida Outline Epidemiology Clinical Overview Why HF is such a challenge State of the Field Heart Failure Adjudication
More informationOptimal blockade of the Renin- Angiotensin-Aldosterone. in chronic heart failure
Optimal blockade of the Renin- Angiotensin-Aldosterone Aldosterone- (RAA)-System in chronic heart failure Jan Östergren Department of Medicine Karolinska University Hospital Stockholm, Sweden Key Issues
More informationReview of FDA Guidance on Cardiovascular Outcomes for Diabetes Medication Trials and Application to Clinical Management
Katherine S. O Neal Pharm.D., MBA, BCACP, CDE, BC-ADM, AE-C Associate Professor The University of Oklahoma Health Sciences Center College of Pharmacy Department of Internal Medicine Oklahoma City, OK Member,
More informationGlucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science
Glucose Lowering Medications and CV Risk Reduction: A New Era Jane EB Reusch MD ADA President for Medicine and Science Professor of Medicine, Division of Endocrinology, Metabolism and Diabetes and Associate
More informationHeart Failure with preserved ejection fraction (HFpEF)
Heart Failure with preserved ejection fraction (HFpEF) Dr. Pierpaolo Pellicori Hull York Medical School Kingston-upon-Hull United Kingdom Conflict of interest: none Heart failure is a contemporary problem
More informationTHE EVOLUTION OF CLINICAL TRIALS IN T2DM: FROM TARGETING A1C TO TARGETING CARDIOVASCULAR OUTCOMES
Learning Objectives 1) Evaluate the interrelationship between diabetes, glycemic control, and cardiovascular disease. 2) Examine the evolution of type 2 diabetes (T2DM) drug development and factors leading
More informationFrom PARADIGM-HF to Clinical Practice. Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group
From PARADIGM-HF to Clinical Practice Waleed AlHabeeb, MD, MHA Associate Professor of Medicine President of the Saudi Heart Failure Group PARADIGM-HF: Inclusion Criteria Chronic HF NYHA FC II IV with LVEF
More informationLEADER Liraglutide and cardiovascular outcomes in type 2 diabetes
LEADER Liraglutide and cardiovascular outcomes in type 2 diabetes Presented at DSBS seminar on mediation analysis August 18 th Søren Rasmussen, Novo Nordisk. LEADER CV outcome study To determine the effect
More informationUnderstanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials -
Understanding and Development of New Therapies for Heart Failure - Lessons from Recent Clinical Trials - Clinical trials Evidence-based medicine, clinical practice Impact upon Understanding pathophysiology
More informationBeta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes
Beta-blockers in Patients with Mid-range Left Ventricular Ejection Fraction after AMI Improved Clinical Outcomes Seung-Jae Joo and other KAMIR-NIH investigators Department of Cardiology, Jeju National
More informationHeart Failure Management. Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist
Heart Failure Management Waleed AlHabeeb, MD, MHA Assistant Professor of Medicine Consultant Heart Failure Cardiologist Heart failure prevalence is expected to continue to increase¹ 21 MILLION ADULTS WORLDWIDE
More informationHeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long. Case Study 2
HeFSSA Practitioners Program 2017 Theme The Patient Journey: Feel Good and Live Long Case Study 2 HEART FAILURE WITH MID-RANGE EJECTION FRACTION TREATMENT OPTIONS CLINICAL CASE MEDICAL HISTORY 59-year-old
More informationCongestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, :30 a.m. 10:15 a.m.
Congestive Heart Failure: The Complication that Gets No Respect Richard J. Katz, MD Saturday, February 18, 2017 9:30 a.m. 10:15 a.m. The prevalence of the combination of diabetes and both systolic and
More informationWhat s new in the 2017 heart failure guidelines. Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA
What s new in the 2017 heart failure guidelines Prof.Dr.Mehmet Birhan YILMAZ, FESC, FACC, FHFA Key points to remember 2017 guidelines recommend using natriuretic peptides as biomarkers to screen for heart
More informationPost Hoc Analysis of the PARADIGM Heart Failure Trial:
Post Hoc Analysis of the PARADIGM Heart Failure Trial: Pulse Pressure and Outcomes in Heart Failure with Reduced Ejection Fraction Chen-Huan Chen, M.D. Professor, Department of Medicine, National Yang-Ming
More informationKnown Actions of Digoxin
Known Actions of Digoxin Hemodynamic effects in heart failure Increases cardiac output, no effect on blood pressure Decreases PCWP Increases LVEF (
More information2017 Summer MAOFP Update
2017 Summer MAOFP Update. Cardiology Update 2017 Landmark Trials Change Practice Guidelines David J. Strobl, DO, FNLA Heart Failure: Epidemiology More than 4 million patients affected 400,000 new cases
More informationUpdate on pharmacological treatment of heart failure. Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy
Update on pharmacological treatment of heart failure Aldo Pietro Maggioni, MD, FESC ANMCO Research Center Firenze, Italy Presenter Disclosures Dr. Maggioni : Serving in Committees of studies sponsored
More informationUpdates in Heart Failure (HF) 2016: ACC / AHA and ESC
Updates in Heart Failure (HF) 2016: ACC / AHA and ESC Patrick McBride, MD, MPH Professor of Medicine & Family Medicine, UW School of Medicine and Public Health Special thanks to: Clyde W. Yancy, MD, MSc
More informationHeart Failure with Preserved Left Ventricular Ejection Fraction. (HFpEF)
Thessaloniki, May 27, 2017 Heart Failure with Preserved Left Ventricular Ejection Fraction Filippos Triposkiadis, MD, FESC, FACC Professor of Cardiology Director, Department of Cardiology Larissa University
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationHeart Failure Update. Chim Lang
Heart Failure Update Chim Lang Heart Failure Patient s Journey Acute Treat and stabilize Initiate monitoring Plan interventions Chronic Optimize drug and device therapy Manage Co-morbidities Subacute
More informationEndocrinologist Sweetgrass Endocrinology
Endocrinologist Sweetgrass Endocrinology Sanders, Cummings Ask Justice Department to Investigate Insulin Prices The Department of Justice and the FTC are asked to investigate whether Lilly, Novo Nordisk,
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationTreating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks
Treating Heart Failure in Biodiverse Patient Populations: Best Practices and Unveiling Disparities in Blacks 12th Annual Leadership Summit on Health Disparities & Congressional Black Caucus Spring Health
More informationDisclosures of Interest. Publications Diabetologia Key points to emphasize
Disclosures of Interest No conflicts or disclosures How to Use the American Diabetes Association s Type 2 Diabetes Treatment Algorithm Rashida Downing, MD, FAAFP Primary Care Physician JenCare Medical
More informationDisclosures for Presenter
A Comparison of Angiotensin Receptor- Neprilysin Inhibition (ARNI) With ACE Inhibition in the Long-Term Treatment of Chronic Heart Failure With a Reduced Ejection Fraction Milton Packer, John J.V. McMurray,
More informationEvaluating the Cardiovascular Benefits of Antidiabetic Medications
Evaluating the Cardiovascular Benefits of Antidiabetic Medications Target Audience: Pharmacists ACPE#: 0202-0000-18-054-L01-P Activity Type: Application-based Disclosures Stuart T. Haines has no relevant
More informationHeart Failure. Guillaume Jondeau Hôpital Bichat, Paris, France
Heart Failure Guillaume Jondeau Hôpital Bichat, Paris, France Epidemiology Importance of PEF Europe I-PREFER study. Abstract: 2835 Prevalence of HF Preserved LV systolic Function older (65 vs 62 y, p
More informationHeart Failure. Disclosures. Objectives: 8/28/2017. This is not a virus. It doesn t go away. none
Heart Failure This is not a virus. It doesn t go away Shelley Wojtaszczyk, FNP-C, CHFN Heart Failure Program Coordinator Mercy Hospital of Buffalo none Disclosures Objectives: Defining and identifying
More informationDISCLAIMER: ECHO Nevada emphasizes patient privacy and asks participants to not share ANY Protected Health Information during ECHO clinics.
DISCLAIMER: Video will be taken at this clinic and potentially used in Project ECHO promotional materials. By attending this clinic, you consent to have your photo taken and allow Project ECHO to use this
More information